Atrial natriuretic peptide (ANP), when administered by intravenous infusion to asthmatic patients, causes a similar degree of bronchodilation to that produced by infused and nebulised salbutamol.'`ANP also protects against both direct and indirect bronchial challenges.45 It is not, however, orally bioavailable and inhalational studies thus far have shown only a modest effect on airway tone and reactivitiy.T he relatively small effects of ANP when given by the inhaled route suggest that it may be being degraded within the airways. ANP is cleaved enzymatically by neutral endopeptidase (NEP); this enzyme is found in airway epithelium and it is of note that concentrations of NEP in the airways are higher than those found in the lung vasculature or parenchyma.9 In vitro we have found that the addition of phosphoramidon, whose actions include the inhibition of NEP, enhances the relaxant and protective effects of ANP on airway smooth muscle.'0
Abstract Background -The hormone atrial natriuretic peptide (ANP) causes bronchodilation and partially protects against direct and indirect bronchial challenges. Both in vitro and in vivo studies have found that the protective effect of ANP against bronchoconstriction is enhanced by inhibition of the enzyme neutral endopeptidase (NEP). It was hypothesised that pretreatment with thiorphan, an NEP inhibitor, might enhance the bronchodilator response to inhaled ANP. Methods -In a randomised double blind placebo controlled crossover study, six asthmatic patients (one woman) of mean (SD) age 47-3 (3.8) years and forced expiratory volume in one second (FEVy) 1 91 (0-42)1, 55 (3-8)% predicted, were studied. All were shown at screening to have at least a 25% improvement in FEVy to inhaled salbutamol. On five study visits the patients received either thiorphan 1 mg (in 2 ml) followed by ANP 5 mg or placebo (saline), or placebo (saline) followed by ANP (5 mg), placebo or salbutamol 5 Atrial natriuretic peptide (ANP), when administered by intravenous infusion to asthmatic patients, causes a similar degree of bronchodilation to that produced by infused and nebulised salbutamol.'`ANP also protects against both direct and indirect bronchial challenges.45 It is not, however, orally bioavailable and inhalational studies thus far have shown only a modest effect on airway tone and reactivitiy.T he relatively small effects of ANP when given by the inhaled route suggest that it may be being degraded within the airways. ANP is cleaved enzymatically by neutral endopeptidase (NEP); this enzyme is found in airway epithelium and it is of note that concentrations of NEP in the airways are higher than those found in the lung vasculature or parenchyma.9 In vitro we have found that the addition of phosphoramidon, whose actions include the inhibition of NEP, enhances the relaxant and protective effects of ANP on airway smooth muscle.'0
In vivo the protective effect of ANP against histamine-induced bronchoconstriction is enhanced by pretreatment with thiorphan,"1 a potent inhibitor of NEP." An alternative approach to harnessing the bronchodilator potential of inhaled ANP on the airway might therefore be to inhibit NEP locally and so prevent the breakdown of exogenously administered ANP.
The present study was designed to determine the effect of preinhalation of thiorphan on the bronchodilator response to inhaled ANP in asthmatic patients. (3 4)%). There was no difference in the maximum degree of bronchodilation following the administration of ANP alone compared with the combination of thiorphan and ANP. With both ANP and the combination of the NEP inhibitor and ANP the degree of bronchodilation was significantly less than that produced by salbutamol which was maximal at one hour (mean (SE) change in FEV, of 53 (10 5)%) and maintained at two hours (fig 1) .
Methods
ANP and cGMP levels were significantly raised at both visits when ANP was ad- 32.
